left-tab

DUPIXENT has been studied up to 1 year in nearly 3000 asthma patients^1,a

Adverse reactions occurring in ≥1% of DUPIXENT + SOC patients and at a higher rate than placebo + SOC in DRI12544 and QUEST (6-month safety pool)

ADVERSE REACTION

ADVERSE
REACTION

Injection site reactions^a

Oropharyngeal pain

Eosinophilia^c

DUPIXENT 200 mg
Q2W + SOC
(n=779) n (%)

ADVERSE REACTION

Injection site
reactions^b

111 (14)

Oropharyngeal
pain

13 (2)

Eosinophilia^c

17 (2)

DUPIXENT 300 mg
Q2W + SOC
(n=788)
n (%)

ADVERSE REACTION

Injection site
reactions^a

144 (18)

Oropharyngeal
pain

19 (2)

Eosinophilia^b

16 (2)

PLACEBO + SOC
(n=792)
n (%)

ADVERSE REACTION

Injection site
reactions^b

50 (6)

Oropharyngeal pain

7 (1)

Eosinophilia^c

2 (<1)

^aThe asthma development program for patients aged 12 years and older included three randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration, which enrolled a total of 2888 subjects.

^bInjection site reactions cluster includes erythema, edema, pruritus, pain, and inflammation.

^cNone met the criteria for serious eosinophilic conditions.

The safety population (DRI12544 and QUEST) was 12-87 years of age, of which 63% were female and 82% were White. DUPIXENT 200 mg or 300 mg was administered subcutaneously Q2W, following an initial dose of 400 mg or 600 mg, respectively
In DRI12544 and QUEST, the proportion of subjects who discontinued treatment due to adverse events was 4% of the placebo + SOC group, 3% of the DUPIXENT 200 mg Q2W + SOC group, and 6% of the DUPIXENT 300 mg Q2W + SOC group

OLE, open-label extension; Q2W, once every 2 weeks; SOC, standard of care.